• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Mauro Sousa

2019-07-26News

What is your current role in EPAD? 

I am a Project Manager at IXICO plc, and I manage the delivery of Magnetic Resonance Imaging (MRI) analysis results on EPAD Longitudinal Cohort Study. IXICO data analysis algorithms quantitatively analyse brain scans, to maximise the information extracted and increase chances of detecting therapy-induced changes in clinical trials. IXICO’s artificial intelligence data analytics will be used to combine imaging with other data captured from EPAD participants, to predict the rate of disease progression in individual participants and identify those people who could benefit from enrolment in clinical trials aimed at preventing Alzheimer’s disease.

What did you do prior to joining EPAD?

I joined the EPAD study on 2016, when the first participants started to be recruited and having MRIs. I have a background on Biomedical Engineering and started working at IXICO in 2014, right after my MSc, in a more technical role. I developed an expertise on the complexities of set-up and training of MRI centres for data acquisition, and used that experience to set-up the majority of the MRI scanners in the study. In 2018 I moved into a position of managing a team that sets up sites and analyses the patient images, which led me to my current role on EPAD.

Tell us a bit about the institution/company/organisation you work for.

IXICO is a company that provides neuroscience expertise and global operations to deliver imaging and digital biomarker analytical services for clinical development, within a framework of regulatory compliance. IXICO values the relationships it has with academia, business and charitable organisations. Only by working together we can advance treatment for neurological diseases. IXICO’s expertise and TrialTracker™ digital platform is being used to standardise the collection and analysis of MRI data on EPAD (as well as PET data on the sister project AMYPAD).

What are your expectations from the EPAD project?

My expectations are that the foundations built/lessons learned from the Longitudinal Cohort Study across the interactions with the impressive number of academic and industry partners will allow for a solid and successful implementation of the adaptive studies. Furthermore, I hope that the output of the work performed by IXICO will have a very positive impact in the set-up and success of the adaptive studies.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the new @AlzheimerEurope report on #DataSharing in #dementia #research, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing. It includes case studies from ADNI, @IMI_EPAD and @IMI_EMIF. ⬇️ Bit.ly/DataSharing_AE twitter.com/AlzheimerEurop…

reply retweet favorite
2:39 pm · 2021-02-23
Twitter
EPAD
EPAD
@IMI_EPAD

Scottish @IMI_EPAD members have been invited to join the first #EPADcommunity meeting. Today, we're discussing about publications, #data access, communications, participant panel, #network & #collaborations. Nice to see some #epadistas sharing their insights 👨‍⚕️👩‍🔬👩‍💻 pic.twitter.com/O1hLAVxk0Q

reply retweet favorite
2:23 pm · 2021-02-17
Twitter
EPAD
EPAD
@IMI_EPAD

The new issue of the @IMI2_NEURONET #newsletter is out with latest news on @IMI_EPAD, @IMI_AMYPAD, @RADARCNS among others. Find out more here: bit.ly/Neuronet-Newsl… twitter.com/IMI2_NEURONET/…

reply retweet favorite
2:12 pm · 2021-02-15
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.